Amgen Inc. (NASDAQ:AMGN) Shares Acquired by JGP Wealth Management LLC

JGP Wealth Management LLC increased its stake in Amgen Inc. (NASDAQ:AMGN) by 3.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 54,470 shares of the medical research company’s stock after buying an additional 1,614 shares during the quarter. Amgen comprises 1.8% of JGP Wealth Management LLC’s portfolio, making the stock its 14th largest position. JGP Wealth Management LLC’s holdings in Amgen were worth $14,197,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of AMGN. Bradley Foster & Sargent Inc. CT grew its position in shares of Amgen by 2.7% in the 2nd quarter. Bradley Foster & Sargent Inc. CT now owns 16,243 shares of the medical research company’s stock worth $5,075,000 after acquiring an additional 424 shares in the last quarter. Blair William & Co. IL grew its position in shares of Amgen by 38.3% in the 2nd quarter. Blair William & Co. IL now owns 187,658 shares of the medical research company’s stock worth $58,634,000 after acquiring an additional 51,957 shares in the last quarter. Waterloo Capital L.P. acquired a new position in shares of Amgen in the 2nd quarter worth approximately $231,000. Seven Eight Capital LP acquired a new position in shares of Amgen in the 2nd quarter worth approximately $845,000. Finally, Marathon Trading Investment Management LLC acquired a new position in shares of Amgen in the 2nd quarter worth approximately $469,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on AMGN. Robert W. Baird reissued an “underperform” rating and issued a $215.00 price target on shares of Amgen in a report on Wednesday, September 25th. TD Cowen raised their price target on Amgen from $381.00 to $383.00 and gave the stock a “buy” rating in a report on Monday, October 21st. StockNews.com downgraded Amgen from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Citigroup cut their price target on Amgen from $335.00 to $310.00 in a report on Wednesday, November 27th. Finally, Piper Sandler Companies reissued an “overweight” rating and issued a $310.00 price target on shares of Amgen in a report on Thursday, January 2nd. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $314.91.

Amgen Price Performance

NASDAQ:AMGN opened at $269.43 on Friday. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96. The firm has a market cap of $144.83 billion, a price-to-earnings ratio of 34.50, a price-to-earnings-growth ratio of 2.68 and a beta of 0.56. The company has a 50 day moving average price of $276.06 and a 200-day moving average price of $307.76. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $346.85.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, topping the consensus estimate of $5.11 by $0.47. The company had revenue of $8.50 billion during the quarter, compared to analyst estimates of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The firm’s revenue was up 23.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $4.96 EPS. Equities research analysts forecast that Amgen Inc. will post 19.57 EPS for the current year.

Amgen Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be paid a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a yield of 3.53%. The ex-dividend date of this dividend is Friday, February 14th. This is a positive change from Amgen’s previous quarterly dividend of $2.25. Amgen’s dividend payout ratio (DPR) is 115.24%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.